Crinetics Pharmaceuticals Inc.

19.61+0.2100+1.08%Vol 1.26M1Y Perf -4.76%
Jun 24th, 2022 16:00 DELAYED
BID15.10 ASK23.99
Open19.37 Previous Close19.40
Pre-Market- After-Market19.61
 - -  - -%
Target Price
44.50 
Analyst Rating
Strong Buy 1.00
Potential %
126.93 
Finscreener Ranking
★★★     49.22
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     54.88
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★+     48.62
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
28.37 
Earnings Rating
Neutral
Market Cap1.05B 
Earnings Date
9th Aug 2022
Alpha-0.01 Standard Deviation0.16
Beta1.42 

Today's Price Range

19.1419.99

52W Range

15.9128.95

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
7.22%
1 Month
12.90%
3 Months
3.43%
6 Months
-26.03%
1 Year
-4.76%
3 Years
-20.51%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CRNX19.610.21001.08
AAPL141.663.39002.45
GOOG2 370.76117.07005.19
MSFT267.708.84003.41
XOM86.901.69001.98
WFC40.762.86007.55
JNJ182.292.63001.46
FB196.640.99000.51
GE67.083.01004.70
JPM117.323.40002.98
Financial StrengthValueIndustryS&P 500US Markets
15.90
16.20
0.01
0.01
-
Leverage Ratio 1.10
ProfitabilityValueIndustryS&P 500US Markets
-
-2 818.00
-2 795.70
-22 521.60
-
RevenueValueIndustryS&P 500US Markets
4.21M
0.08
-40.33
-21.29
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.56-0.73-30.36
Q04 2021-0.57-0.68-19.30
Q03 2021-0.70-0.73-4.29
Q02 2021-0.60-0.70-16.67
Q01 2021-0.65-0.69-6.15
Q04 2020-0.58-0.66-13.79
Q03 2020-0.52-0.56-7.69
Q02 2020-0.52-0.53-1.92
Earnings Per EndEstimateRevision %Trend
6/2022 QR-0.621.59Positive
9/2022 QR-0.641.54Positive
12/2022 FY-2.69-5.91Negative
12/2023 FY-2.81-4.85Negative
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.62
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume1.26M
Shares Outstanding53.51K
Shares Float46.90M
Trades Count6.63K
Dollar Volume24.77M
Avg. Volume360.67K
Avg. Weekly Volume399.53K
Avg. Monthly Volume337.58K
Avg. Quarterly Volume344.88K

Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) stock closed at 19.61 per share at the end of the most recent trading day (a 1.08% change compared to the prior day closing price) with a volume of 1.26M shares and market capitalization of 1.05B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 68 people. Crinetics Pharmaceuticals Inc. CEO is R. Scott Struthers.

The one-year performance of Crinetics Pharmaceuticals Inc. stock is -4.76%, while year-to-date (YTD) performance is -30.98%. CRNX stock has a five-year performance of %. Its 52-week range is between 15.91 and 28.95, which gives CRNX stock a 52-week price range ratio of 28.37%

Crinetics Pharmaceuticals Inc. currently has a PE ratio of -6.50, a price-to-book (PB) ratio of 3.23, a price-to-sale (PS) ratio of 232.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.05%, a ROC of -52.14% and a ROE of -52.76%. The company’s profit margin is -%, its EBITDA margin is -2 795.70%, and its revenue ttm is $4.21 Million , which makes it $0.08 revenue per share.

Of the last four earnings reports from Crinetics Pharmaceuticals Inc., there were 0 positive earnings surprise and 4 negative earnings surprise. The company has EPS estimate of $-0.62 for the next earnings report. Crinetics Pharmaceuticals Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for Crinetics Pharmaceuticals Inc. is Strong Buy (1), with a target price of $44.5, which is +126.93% compared to the current price. The earnings rating for Crinetics Pharmaceuticals Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Crinetics Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Crinetics Pharmaceuticals Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 8.57, ATR14 : 1.35, CCI20 : 102.88, Chaikin Money Flow : 0.08, MACD : -0.08, Money Flow Index : 70.32, ROC : 0.20, RSI : 55.28, STOCH (14,3) : 65.95, STOCH RSI : 1.00, UO : 54.25, Williams %R : -34.05), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Crinetics Pharmaceuticals Inc. in the last 12-months were: Ajay Madan (Option Excercise at a value of $77 660), Ajay Madan (Sold 13 411 shares of value $239 085 ), Alan Krasner (Option Excercise at a value of $80 467), Alan Krasner (Sold 6 700 shares of value $142 080 ), Matthew K. Fust (Option Excercise at a value of $57 300), Matthew K. Fust (Sold 30 000 shares of value $681 500 ), R. Scott Struthers (Sold 170 000 shares of value $4 510 850 ), Stephen F. Betz (Sold 94 658 shares of value $2 346 606 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
6 (100.00 %)
6 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Crinetics Pharmaceuticals Inc.

Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

CEO: R. Scott Struthers

Telephone: +1 858 450-6464

Address: 10222 Barnes Canyon Road, San Diego 92121, CA, US

Number of employees: 68

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

80%20%

Bearish Bullish

69%31%

Bearish Bullish

53%47%

TipRanks News for CRNX

Fri, 10 Jun 2022 12:12 GMT Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from J.P. Morgan

- TipRanks. All rights reserved.

Fri, 27 May 2022 04:37 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from Evercore ISI

- TipRanks. All rights reserved.

Tue, 17 May 2022 04:16 GMT Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO), Crinetics Pharmaceuticals (CRNX) and Harpoon Therapeutics (HARP)

- TipRanks. All rights reserved.

Mon, 16 May 2022 10:17 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from H.C. Wainwright

- TipRanks. All rights reserved.

Sun, 03 Apr 2022 10:42 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from J.P. Morgan

- TipRanks. All rights reserved.

Sat, 02 Apr 2022 02:25 GMT Crinetics Pharmaceuticals (CRNX) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 06:55 GMT Crinetics Pharmaceuticals (CRNX) Gets a Buy Rating from JMP Securities

- TipRanks. All rights reserved.

Mon, 28 Feb 2022 13:45 GMT Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and ATI Physical Therapy (ATIP)

- TipRanks. All rights reserved.

News

Stocktwits